ストックスクリーナーアプリを入手
47.04
0.38%
-0.18
アフターアワーズ：
46.50
-0.54
-1.15%
前日終値:
$47.22
開ける：
$47.3
24時間の取引高:
589.28K
Relative Volume:
1.29
時価総額：
$2.26B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+7.03%
1か月 パフォーマンス:
+17.04%
6か月 パフォーマンス:
+242.36%
1年 パフォーマンス:
+292.65%
1日の値動き範囲:
$45.51
$47.85
1週間の範囲:
$42.79
$48.52
52週間の値動き範囲:
$6.71
$49.25
Maze Therapeutics Inc Stock (MAZE) Company Profile
名前
Maze Therapeutics Inc
セクター
電話
(650) 850-5070
住所
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
47.04 | 2.27B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | 開始されました | Wells Fargo | Overweight |
| 2025-11-14 | 開始されました | Raymond James | Outperform |
| 2025-09-02 | 開始されました | BTIG Research | Buy |
| 2025-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-08 | 開始されました | Wedbush | Outperform |
Maze Therapeutics Inc (MAZE) 最新ニュース
IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn
Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics Secures New $200 Million Loan Facility - TipRanks
Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock - Defense World
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - aol.com
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock - MarketBeat
Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - The Motley Fool
Maze Therapeutics, Inc. (MAZE): Investor Outlook And 9.88% Potential Upside - DirectorsTalk Interviews
Washington University Takes Position in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com Canada
Equities Analysts Set Expectations for MAZE FY2030 Earnings - MarketBeat
Maze Therapeutics Rings the Closing Bell - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Raised to "Hold" at Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts - MarketBeat
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Strong Buy Ratings Amid Potential 7% Upside - DirectorsTalk Interviews
Retail Surge: What’s the fair value of Maze Therapeutics Inc. stockQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - mfd.ru
First Week of March 20th Options Trading For Maze Therapeutics (MAZE) - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $46.00 - Defense World
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
BTIG Research Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $46.00 - MarketBeat
Maze Therapeutics: An Innovative, Nature-Driven Platform (NASDAQ:MAZE) - Seeking Alpha
Assessing Maze Therapeutics (MAZE) Valuation After Its Recent Share Price Momentum - Sahm
What dividend safety score for Maze Therapeutics Inc. stockInflation Watch & Proven Capital Preservation Tips - Bộ Nội Vụ
Gainers Report: How Maze Therapeutics Inc stock valuations compare to rivals2025 Technical Patterns & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
How Maze Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Final Week & Risk Managed Investment Entry Signals - Улправда
How Maze Therapeutics Inc. stock valuations compare to rivalsStock Surge & Low Risk Profit Maximizing Plans - Улправда
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 25,156 Shares - MarketBeat
Maze Therapeutics (MAZE) Stock Analysis: Exploring a 21.52% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale - TipRanks
How rising interest rates impact Maze Therapeutics Inc. stock2025 Sector Review & Daily Momentum Trading Reports - Улправда
How Maze Therapeutics Inc. stock reacts to oil pricesJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - Улправда
Is Maze Therapeutics Inc. stock trading at a premium valuation2025 Bull vs Bear & Safe Capital Growth Stock Tips - Улправда
What sentiment indicators say about Maze Therapeutics Inc. stockQuarterly Profit Summary & Reliable Price Breakout Alerts - Улправда
Is Maze Therapeutics Inc. stock supported by innovation pipeline2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 412 Shares of Stock - MarketBeat
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BERNSTEIN HAROLD Insider Trades - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 4.9% – Here’s Why - Defense World
Maze Therapeutics Inc (MAZE) 財務データ
Maze Therapeutics Inc (MAZE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):